Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
Allogene Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 26, 2022
Allogene Therapeutics reported fiscal year 2021 executive compensation information on April 26, 2022.
In 2021, five executives at Allogene Therapeutics received on average a compensation package of $6M, a 68% increase compared to previous year.
Average pay of disclosed executives at Allogene Therapeutics
David Chang, Chief Executive Officer, received $10M in total, which increased by 30% compared to 2020. 63% of Chang's compensation, or $6.4M, was in option awards. Chang also received $396K in non-equity incentive plan, $695K in salary, as well as $2.7M in stock awards.
Rafael Amado, Chief Medical Officer, received a compensation package of $9.7M, which increased by 265% compared to previous year. 70% of the compensation package, or $6.8M, was in stock awards.
Alison Moore, Chief Technical Officer, earned $3.5M in 2021, a 43% increase compared to previous year.
Eric Schmidt, Chief Financial Officer, received $3.5M in 2021, which increases by 39% compared to 2020.
Veer Bhavnagri, General Counsel, earned $3.2M in 2021, a 32% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 26, 2022.